Exposure to biologics during pregnancy does not affect placental antibody transfer of anti-SARS-CoV-2 neutralizing antibodies, but concomitant corticosteroid exposure may decrease... by Donna E. Leet (22772478)

Study-related adverse events. by Benjamin R. Lewis (22279166)

“…We recorded 12 study-related, Grade 1–2 AEs and no serious AEs. In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”

Study flow chart. by Benjamin R. Lewis (22279166)

“…We recorded 12 study-related, Grade 1–2 AEs and no serious AEs. In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”

Study CONSORT diagram. by Benjamin R. Lewis (22279166)

“…We recorded 12 study-related, Grade 1–2 AEs and no serious AEs. In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; <i>p</i> = 0.008). …”

Patients’ demographics and clinical parameters. by Zi-Rong Chen (9227618)

Loss of mammary fitness and virulence by <i>M</i>. <i>bovis</i> 0690::Tn mutant. by Aga E. Gelgie (17661720)

Basic information and patient characteristics according to the report. by Xiaoling Zhong (181270)

Demographics of the study population. by Sohyun Park (78358)

“…In the comparison among the ipsilateral, contralateral side of iPD with clinical laterality, and disease control group, the OBH of the disease control group was significantly larger than both the ipsilateral and contralateral sides (<i>P</i> < 0.05). …”

Table 3 - by Sohyun Park (78358)

“…In the comparison among the ipsilateral, contralateral side of iPD with clinical laterality, and disease control group, the OBH of the disease control group was significantly larger than both the ipsilateral and contralateral sides (<i>P</i> < 0.05). …”

GO and KEGG analysis of DEPs. by Huiyang Jia (14444661)

Data Sheet 1_Exploring long COVID in pediatric patients: clinical insights from a long COVID clinic.docx by Dina Kamel (22434430)

“…</p>Methods<p>We conducted a retrospective study of patients aged 0–21 years evaluated at the Long COVID Clinic at Children's Hospital Los Angeles between August 2021 and November 2023. …”

Data extracted from the included studies. by Jesse Hill (19929059)

“…Three studies reported an increase in the proportion of patients admitted after introducing an ADP, one of which was significant while 15 studies reported a significant decrease in admission proportion. …”

Risk of bias assessments for controlled trials. by Jesse Hill (19929059)

“…Three studies reported an increase in the proportion of patients admitted after introducing an ADP, one of which was significant while 15 studies reported a significant decrease in admission proportion. …”

Estimating RSA Variability across Treatment, Time, and Condition. by Hikari Otsuka (18605246)

Characteristics of the study participants. by Michał Wendt (17601180)

“…A significant time effect was also observed for PPT, with an increase in the right-side threshold (p = 0.0186; d = 0.58). …”

Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”

Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

“…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”